Insights - Tax inversion has been a trend in the biotech and pharmaceutical industry, involvinga U.S.-based company acquiring a smaller foreign company in order to reduce paid … Continue Reading
Read NowInsights - Pozen (POZN) shares dropped on news that the FDA has accepted for review the refiling of a NDA for two aspirin candidates, PA8140 and -32540. … Continue Reading
Read NowInsights - La Jolla Pharmaceutical (LJPC) shares jumped 21% in early trading on Tuesday following news that pipeline candidate LJPC-1010 demonstrated positive activity in a pre-clinical model … Continue Reading
Read NowInsights - Exelixis (EXEL) on Monday announced positive top-line results from a phase 3 trial of the MEK inhibitor cobimetinib in combination with Zelboraf (vemurafenib) in untreated patients with melanoma harboring … Continue Reading
Read NowInsights - The FDA has informed Salix Pharmaceuticals (SLXP) that Relistor (methylnaltrexone bromide) can be approved for the treatment of constipation in patients taking opioids for chronic non-cancer … Continue Reading
Read NowInsights - Lexicon Pharmaceuticals (LXRX) will partner with JDRF (Juvenile Diabetes Research Foundation) for a phase 2 study of LX4211 in younger Type 1 Diabetes (T1D) patients (<30 … Continue Reading
Read NowInsights - Celgene (CELG) said on Wednesday morning that a phase 3 trial of Otezla, the company’s oral inhibitor of phosphodiesterase 4 (PDE4) already approved in active psoriatic … Continue Reading
Read Now
